ManuelDGLeungMNguyenKBurden of cardiovascular disease in Canada. Can J Cardiol2003;19(9):997–1004.
2.
McPhersonRFrohlichJFodorJCanadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol2006;22:913–27.
3.
PearsonGJThompsonAESemchukW. 2007 guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. Can Pharm J2007;140(6):383–8.
4.
MaronDJFazioSLintonMF. Current perspectives on statins. Circulation2000:101:207–13.
5.
WoodD. Asymptomatic individuals — risk stratification in the prevention of coronary heart disease. Br Med Bulletin2001;59:3–16.
6.
HarringtonRABeckerRCEzekowitzMAntithrombotic therapy for coronary artery disease. Chest2004;126:513–48.
7.
D'AgostinoRBVasanRSPencinaMJGeneral cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation2008;117:743–53.
8.
RidkerPMBuringJERifaiNDevelopment and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA2007;297:611–19.
9.
GroverSALowensteynIJosephLPatient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP Study: a randomized controlled trial. Arch Intern Med2007;167:2296–303.
10.
ItoMK. Role of the pharmacist in establishing lipid intervention programs. Pharmacotherapy2003;23(9 Pt 2):41S–47S.
